02 April 2024
02 April 2024
Voydeya is intended for patients who continue to suffer from EVH despite treatment with C5 inhibitors.
Vemlidy was first approved to treat adults with HBV in 2016. Its label was expanded in 2022 for use in patients 12 years and older.
Merz placed a “stalking horse bid” for Acorda’s Parkinson’s disease and multiple sclerosis treatments.
Eisai is pursuing FDA authorisations for both its monthly IV maintenance and weekly subcutaneous regimens of Leqembi.
The company will focus its resources on clinical development plans for two Phase I candidates, including an asset licenced to Gilead.
Eisai plans to complete the transfer of marketing capabilities by March 2025.
The medication represents the first oral treatment option for adults with mild to moderate Type 1 Gaucher disease.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
